Cargando…
Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the eff...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627684/ https://www.ncbi.nlm.nih.gov/pubmed/31141992 http://dx.doi.org/10.3390/cancers11060738 |
_version_ | 1783434794636410880 |
---|---|
author | Vocka, Michal Zimovjanova, Martina Bielcikova, Zuzana Tesarova, Petra Petruzelka, Lubos Mateju, Martin Krizova, Ludmila Kotlas, Jaroslav Soukupova, Jana Janatova, Marketa Zemankova, Petra Kleiblova, Petra Novotny, Jan Konopasek, Bohuslav Chodacka, Martina Brychta, Milan Sochor, Marek Smejkalova-Musilova, Denisa Cmejlova, Vlastimila Kozevnikovova, Renata Miskarova, Lenka Argalacsova, Sona Stolarova, Lenka Lhotova, Klara Borecka, Marianna Kleibl, Zdenek |
author_facet | Vocka, Michal Zimovjanova, Martina Bielcikova, Zuzana Tesarova, Petra Petruzelka, Lubos Mateju, Martin Krizova, Ludmila Kotlas, Jaroslav Soukupova, Jana Janatova, Marketa Zemankova, Petra Kleiblova, Petra Novotny, Jan Konopasek, Bohuslav Chodacka, Martina Brychta, Milan Sochor, Marek Smejkalova-Musilova, Denisa Cmejlova, Vlastimila Kozevnikovova, Renata Miskarova, Lenka Argalacsova, Sona Stolarova, Lenka Lhotova, Klara Borecka, Marianna Kleibl, Zdenek |
author_sort | Vocka, Michal |
collection | PubMed |
description | Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the effect of clinicopathological characteristics on BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]) in hereditary BRCA1/BRCA2 mutation carriers. We enrolled 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers, of whom 191 carriers and 680 non-carriers, with complete data, were available for survival analyses. We found that patients with ER-positive tumors developed disease recurrence 2.3-times more likely when they carried a BRCA1/BRCA2 mutation (23/60; 38.3% ER-positive carriers vs. 74/445; 16.6% ER-positive non-carriers; p < 0.001). ER-positive mutation carriers also had a 3.4-times higher risk of death due to BC compared with ER-positive non-carriers (13/60; 21.7% vs. 28/445; 6.3%; p < 0.001). Moreover, prognosis in ER-negative BRCA1/BRCA2 mutation carriers was comparable with that in ER-positive non-carriers. Our study demonstrates that ER-positivity worsens BC prognosis in BRCA1/BRCA2 mutation carriers, while prognosis for carriers with ER-negative tumors (including early-onset) is significantly better and comparable with that in ER-positive, older BC non-carriers. These observations indicate that BRCA1/BRCA2 mutation carriers with ER-positive BC represent high-risk patients. |
format | Online Article Text |
id | pubmed-6627684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66276842019-07-23 Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers Vocka, Michal Zimovjanova, Martina Bielcikova, Zuzana Tesarova, Petra Petruzelka, Lubos Mateju, Martin Krizova, Ludmila Kotlas, Jaroslav Soukupova, Jana Janatova, Marketa Zemankova, Petra Kleiblova, Petra Novotny, Jan Konopasek, Bohuslav Chodacka, Martina Brychta, Milan Sochor, Marek Smejkalova-Musilova, Denisa Cmejlova, Vlastimila Kozevnikovova, Renata Miskarova, Lenka Argalacsova, Sona Stolarova, Lenka Lhotova, Klara Borecka, Marianna Kleibl, Zdenek Cancers (Basel) Article Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the effect of clinicopathological characteristics on BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]) in hereditary BRCA1/BRCA2 mutation carriers. We enrolled 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers, of whom 191 carriers and 680 non-carriers, with complete data, were available for survival analyses. We found that patients with ER-positive tumors developed disease recurrence 2.3-times more likely when they carried a BRCA1/BRCA2 mutation (23/60; 38.3% ER-positive carriers vs. 74/445; 16.6% ER-positive non-carriers; p < 0.001). ER-positive mutation carriers also had a 3.4-times higher risk of death due to BC compared with ER-positive non-carriers (13/60; 21.7% vs. 28/445; 6.3%; p < 0.001). Moreover, prognosis in ER-negative BRCA1/BRCA2 mutation carriers was comparable with that in ER-positive non-carriers. Our study demonstrates that ER-positivity worsens BC prognosis in BRCA1/BRCA2 mutation carriers, while prognosis for carriers with ER-negative tumors (including early-onset) is significantly better and comparable with that in ER-positive, older BC non-carriers. These observations indicate that BRCA1/BRCA2 mutation carriers with ER-positive BC represent high-risk patients. MDPI 2019-05-28 /pmc/articles/PMC6627684/ /pubmed/31141992 http://dx.doi.org/10.3390/cancers11060738 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vocka, Michal Zimovjanova, Martina Bielcikova, Zuzana Tesarova, Petra Petruzelka, Lubos Mateju, Martin Krizova, Ludmila Kotlas, Jaroslav Soukupova, Jana Janatova, Marketa Zemankova, Petra Kleiblova, Petra Novotny, Jan Konopasek, Bohuslav Chodacka, Martina Brychta, Milan Sochor, Marek Smejkalova-Musilova, Denisa Cmejlova, Vlastimila Kozevnikovova, Renata Miskarova, Lenka Argalacsova, Sona Stolarova, Lenka Lhotova, Klara Borecka, Marianna Kleibl, Zdenek Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers |
title | Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers |
title_full | Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers |
title_fullStr | Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers |
title_full_unstemmed | Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers |
title_short | Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers |
title_sort | estrogen receptor status oppositely modifies breast cancer prognosis in brca1/brca2 mutation carriers versus non-carriers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627684/ https://www.ncbi.nlm.nih.gov/pubmed/31141992 http://dx.doi.org/10.3390/cancers11060738 |
work_keys_str_mv | AT vockamichal estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT zimovjanovamartina estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT bielcikovazuzana estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT tesarovapetra estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT petruzelkalubos estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT matejumartin estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT krizovaludmila estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT kotlasjaroslav estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT soukupovajana estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT janatovamarketa estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT zemankovapetra estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT kleiblovapetra estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT novotnyjan estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT konopasekbohuslav estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT chodackamartina estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT brychtamilan estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT sochormarek estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT smejkalovamusilovadenisa estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT cmejlovavlastimila estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT kozevnikovovarenata estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT miskarovalenka estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT argalacsovasona estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT stolarovalenka estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT lhotovaklara estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT boreckamarianna estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers AT kleiblzdenek estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers |